GlassScriptPhysician profile
Jennifer Aversano
NPI 1568109254
$1,313.33
in general payments reported to CMS, 2019-2025
16 companies · $20.58 in 2025
The $20.58 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $301 · 2024: $991 · 2025: $20.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $750 · Food and Beverage: $472 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $750.00 |
| Food and Beverage | $472.38 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $750.00 | 2024 | |
| Gilead Sciences, INC. | $121.05 | 2023 | Trodelvy |
| Merck Sharp & Dohme LLC | $114.47 | 2023-2024 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $47.71 | 2023-2024 | Libtayo |
| Celgene Corporation | $43.70 | 2024 | Reblozyl |
| Incyte Corporation | $41.46 | 2023 | Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $24.89 | 2024 | |
| Beigene USA, INC. | $24.16 | 2024 | Brukinsa |
| Abbvie INC. | $22.28 | 2024 | |
| Adaptive Biotechnologies Corporation | $20.58 | 2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $19.68 | 2024 | |
| Amgen INC. | $18.25 | 2024 | Lumakras |
| Rigel Pharmaceuticals, INC. | $17.23 | 2024 | Tavalisse, Rezlidhia |
| Mirati Therapeutics, INC. | $16.41 | 2024 | Krazati |
| Emd Serono, INC. | $16.14 | 2023 | Bavencio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $15.32 | 2023 | Imbruvica, Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Aversano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.